<p>Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial</p>
International Journal of COPD2020Vol. Volume 15, pp. 2399–2409
Citations Over TimeTop 10% of 2020 papers
Steven M. Rowe, Ieuan Jones, Mark T. Dransfield, Nazmul Haque, Stephen Gleason, Katy Hayes, Kenneth Kulmatycki, Denise P. Yates, Henry Danahay, Martin Gosling, David J. Rowlands, Sarah Schmidt Grant
Abstract
The CFTR potentiator icenticaftor increased FEV1 versus placebo after 28 days and was associated with improvements in systemic inflammation and sputum bacterial colonization in COPD patients; no improvements in LCI with icenticaftor were observed.
Related Papers
- → Chronic obstructive pulmonary disease (COPD)(2021)23 cited
- → Animal Models of Chronic Obstructive Pulmonary Disease(2011)5 cited
- → Nonsmoker COPD: Is it a reality?(2017)1 cited
- [Risk factors of chronic obstructive pulmonary disease in patients with chronic bronchitis].(2001)
- Risk factors of chronic obstructive pulmonary disease in patients with chronic bronchitis(2001)